Last Posted: Nov 02, 2017
- HSD3B1 Genotype and Outcomes With ADT After Radiotherapy for Localized Prostate Cancer
ASCO Post, Nov 1, 2017 - HSD3B1 - A Predictive Biomarker in Advanced Prostate Cancer
AW Hahn et al, JAMA Oncology, Oct 12, 2017 - Utilization of individualized prostate cancer and genomic biomarkers for the practicing urologist.
McMahon Gregory C et al. Reviews in urology 2017 19(2) 97-105 - HSD3B1—A Predictive Biomarker in Advanced Prostate Cancer
AW Hahn et al, JAMA Oncology, Oct 12, 2017 - A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
Van Den Eeden Stephen K et al. European urology 2017 Oct - Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa).
Leapman Michael S et al. PloS one 2017 12(10) e0185535 - Effects of increasing the PSA cutoff to perform additional biomarker tests before prostate biopsy.
Nordström Tobias et al. BMC urology 2017 Oct 17(1) 92 - Clinical utility of emerging liquid biomarkers in advanced prostate cancer.
Vandekerkhove Gillian et al. Cancer genetics 2017 Aug - Genomic Scores are Independent of Disease Volume in Men with Favorable Risk Prostate Cancer: Implications for Choosing Men for Active Surveillance.
Nyame Yaw A et al. The Journal of urology 2017 Sep - Validation of GEMCaP as a DNA based biomarker to predict prostate cancer recurrence after radical prostatectomy.
Nguyen Hao G et al. The Journal of urology 2017 Sep - The impact of a family history of prostate cancer on the prognosis and features of the disease in Korea: results from a cross-sectional longitudinal pilot study.
Lee Kwang Suk et al. International urology and nephrology 2017 Sep - Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model.
Dalela Deepansh et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Jun 35(18) 1982-1990 - Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy.
Beltran Himisha et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2017 Aug - Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores.
Lecarpentier Julie et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Jul 35(20) 2240-2250 - Providing guidance for genomics-based cancer treatment decisions: insights from stakeholder engagement for post-prostatectomy radiation therapy.
Abe James et al. BMC medical informatics and decision making 2017 Aug 17(1) 128 - AMBIGUITY IN A MASCULINE WORLD: Being a BRCA1/2 mutation carrier and a man with prostate cancer.
Moynihan C et al. Psycho-oncology 2017 Aug
.png)
No hay comentarios:
Publicar un comentario